Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.18−0.15 (-11.28%)
Close on Nov 13, 2026Market cap $118.40MP/E –Yield –
Cellectis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$0.67. The highest annual figure on record is -$0.41 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.67 | – |
| FY2024 | Dec 31, 2024 | -$0.41 | – |
| FY2023 | Dec 31, 2023 | -$1.77 | – |
| FY2022 | Dec 31, 2022 | -$2.33 | – |
| FY2021 | Dec 31, 2021 | -$2.55 | – |
| FY2020 | Dec 31, 2020 | -$1.91 | – |
| FY2019 | Dec 31, 2019 | -$2.41 | – |
| FY2018 | Dec 31, 2018 | -$1.93 | – |
| FY2017 | Dec 31, 2017 | -$2.78 | – |
| FY2016 | Dec 31, 2016 | -$1.91 | – |
| FY2015 | Dec 31, 2015 | -$0.67 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.22 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.24 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.28 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.20 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.42 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.88 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.76 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.79 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?